(3-甲基-[1,1-联苯]-4-基)甲醇 | 773872-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-甲基-[1,1-联苯]-4-基)甲醇
• 英文名称: 3’-methylbiphenyl-4-ylmethanol
• 英文别名: 3'-methylbiphenyl-4-ylmethanol；[4-(m-tolyl)phenyl]methanol；(3'-Methyl-[1,1'-biphenyl]-4-yl)methanol；[4-(3-methylphenyl)phenyl]methanol
• CAS: 773872-33-6
• 化学式: C₁₄H₁₄O
• mdl: MFCD05979675
• 分子量: 198.265
• InChiKey: AWWJGVBHUYQLEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  345.7±21.0 °C(Predicted)
• 密度：
  1.072±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2906299090

反应信息

• 作为反应物：
  描述：

  (3-甲基-[1,1-联苯]-4-基)甲醇 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 32.0h， 生成 [4-(m-tolyl)phenyl]methyl N-[(3S)-2-oxoazetidin-3-yl]carbamate
  参考文献：
  名称：

  [EN] CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  [FR] DÉRIVÉS DE CARBAMATE D'INHIBITEURS D'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA) À BASE DE LACTAME

  摘要：

  公开号：

  WO2014144836A3
• 作为产物：
  描述：

  3’-甲基联苯-4-甲酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 1.0h， 以88%的产率得到(3-甲基-[1,1-联苯]-4-基)甲醇
  参考文献：
  名称：

  [EN] CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  [FR] DÉRIVÉS DE CARBAMATE D'INHIBITEURS D'AMIDASE ACIDE DE N-ACYLÉTHANOLAMINE (NAAA) À BASE DE LACTAME

  摘要：

  公开号：

  WO2014144836A3

文献信息

• SUBSTITUTED BIARYL COMPOUND
  申请人：UBE Industries, Ltd.

  公开号：EP2980075A1

  公开（公告）日：2016-02-03

  The present invention provides a substituted biaryl compound of general formula (I): wherein, R1, W, R2, and Z are as defined in the claims and the description, or a pharmacologically acceptable salt thereof. The compound according to the present invention has an excellent inhibition effect of pulmonary fibroblast proliferation, and is therefore useful as a therapeutic agent and/or a prophylactic agent for interstitial pneumonia and pulmonary fibrosis.

  本发明提供了一种通式（I）的取代联苯化合物： 其中，R1、W、R2和Z如权利要求和描述中所定义，或其药理学上可接受的盐。根据本发明的化合物具有优异的抑制肺成纤维细胞增殖的效果，因此可用作间质性肺炎和肺纤维化的治疗剂和/或预防剂。
• SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS
  申请人：Corte James R.

  公开号：US20090062287A1

  公开（公告）日：2009-03-05

  The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , and ring B are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物：或其立体异构体，互变异构体，药学上可接受的盐或溶剂形式，其中变量A、L、Z、R3和环B的定义如本文所述。式（I）的化合物可作为凝血级联反应和/或接触激活系统的丝氨酸蛋白酶酶的选择性抑制剂，例如凝血酶、因子Xa、因子XIa、因子IXa、因子VIIa和/或血浆激肽。特别地，本发明涉及选择性因子XIa抑制剂的化合物。本发明还涉及包含这些化合物的制药组合物和使用它们治疗血栓栓塞性和/或炎症性疾病的方法。
• CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS
  申请人：The Regents of the University of California

  公开号：US20160068482A1

  公开（公告）日：2016-03-10

  Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

  本文描述了一些化合物和药物组成物，它们可以抑制N-酰基乙醇胺酸酰化酶（NAAA）。本文还描述了合成这些化合物的方法，以及将它们制成药物组成物的方法。同时，本文还描述了抑制NAAA以维持棕榈酰乙醇胺（PEA）和其他N-酰基乙醇胺（NAE）的水平的方法，这些物质是NAAA的底物，并且在NAE浓度降低的情况下有用。此外，本文还描述了治疗和缓解疼痛、炎症、炎症性疾病和其他疾病的方法，这些疾病中脂肪酸乙醇胺的调节在临床或治疗上是相关的，或者NAE的浓度降低与该疾病有关。
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US20160158207A1

  公开（公告）日：2016-06-09

  The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R 1 -R 4 of formula (I) and R 1 -R 3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

  本发明涉及公式（I）或公式（II）的化合物及其盐，其中公式（I）的R1-R4和公式（II）的R1-R3具有以下定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括含有公式（I）或公式（II）的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和盐治疗各种CBP和/或EP300介导的疾病的方法。
• N-donor 2-(Sulfonamido)benzamide ligands, their palladium(II) coordination species and C–C coupling catalysis efficiencies
  作者：Hammed Olawale Oloyede、Helmar Görls、Joseph Anthony Orighomisan Woods、Winfried Plass、Abiodun Omokehinde Eseola

  DOI：10.1016/j.molstruc.2019.07.054

  日期：2019.12

  A series of synthetically accessible ligands based on new 2-(R-sulfonamido)benzamide have been prepared (R = methyl for H3M; R = 4-toly for H3T and T2CN; R = 2,4,6-triisopropylphenyl for H(3)iP and HiPCN). The R-substituents were selected to vary in sizes. Allowing ligand H(3)iP and palladium acetate to stand in solvent leads to self-assembly of the well-defined solvent- and stoichiometry-controlled tetranuclear or hexanuclear coordination macromolecules Pd-4(iP)(2) and (PdHiP)(6), which were analysed by X-ray crystallography. It was observed that palladium active species for Suzuki coupling catalysis could be stabilized by these simple and synthetically assessable N-donor ligands as revealed by turnover frequencies reaching 5500h(-1). Electronic features of these N-donors appear to be more important than the steric properties. (C) 2019 Elsevier B.V. All rights reserved.